How do you approach patients with driver mutation positive, Stage IV NSCLC who don't benefit from upfront first-line TKI?
Although a small subset, do you generally move these patients directly on to chemotherapy +/- immunotherapy or does it depend on the specific mutation?
1 Answer
Mednet Member
Medical Oncology · West Virginia University Cancer Institute
Answered on
It depends on the mutation.
EGFR mutants after Osimertinib:
- If oligometastatic disease: an option is radiation to the oligometastatic spots and continue osimertinib. It is important to re-biopsy as well due to the possibility of small cell transformation. If transformed to small cell, in general, c...
Join for free or sign in to see the full answer